PDC Therapeutics is a biotechnology start-up developing targeted Polymer-Drug Conjugate technologies that aim to provide patients with an optimal therapeutic index. PDC Therapeutics’ proprietary Sagitta® biodegradable conjugation platforms help discover and develop therapies with no compromise with a versatile targeting capability. Cooperating with multinational pharmaceutical companies through co-development programs, PDC Therapeutics is supported by an industry-experienced board of scientific and supervisory experts around the world.
Company Details
- Employees
- 6
- Founded
- -
- Address
- Lausanne, Ch
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://pdcbio.com
- Keywords
- biotechnology.
- HQ
- Lausanne
Pdc Therapeutics Questions
Pdc Therapeutics's website is https://pdcbio.com
Pdc Therapeutics's LinkedIn profile is https://ch.linkedin.com/company/pdc-bio
Pdc Therapeutics has
6 employees.
View email and phone details for 6
employees at Pdc Therapeutics.
Pdc Therapeutics's industry is
Biotechnology Research
Pdc Therapeutics's top competitors are
Fluosphera,
Nxi Therapeutics Ag,
Cellula Therapeutics Sa,
Amgen,
Limula,
Milpod,
Swiss Biotech Association,
Rs Research,
Exogems Sa,
Center For Targeted Therapy Technologies - Ct3.
Pdc Therapeutics's categories are Biotechnology Research
Pdc Therapeutics's founding year is 2020
